

FIRST PLACEMENT OF APAS® INDEPENDENCE INTO EUROPEAN LAB

Laboratory Dr Wisplinghoff (Cologne) - largest clinical lab in Germany and one of the largest labs in Europe

Adelaide, Australia, 24 April 2018: LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence (**AI**), is pleased to announce that its joint venture company Clever Culture Systems AG (**CCS**), has shipped an APAS® Independence instrument to a key opinion leader laboratory in Germany. This non-sale shipment is the first APAS® instrument shipped to an operational setting in the northern hemisphere.

Following an extensive review of the APAS® AI technology in the Company's facilities in Adelaide and at St Vincent's Hospital in Melbourne, prestigious German facility Labor Dr Wisplinghoff in Cologne has commissioned its first APAS® Independence instrument. This production-ready instrument has shipped to Germany and will be commissioned by CCS technical staff with scientists at the Labor Dr Wisplinghoff facility, following the ECCMID meeting in Madrid on 21-24 April 2018.

Labor Dr Wisplinghoff is the largest clinical laboratory in Germany and one of the largest laboratories in Europe. Based in a newly completed purpose-built laboratory facility in Cologne, Labor Dr Wisplinghoff services hospitals and medical practices. The laboratory, founded in 1977, boasts over 40 medical specialists covering all relevant areas of clinical pathology including clinical microbiology and virology, clinical chemistry, toxicology, endocrinology, haematology, oncology, genetics, anatomical and molecular pathology and cytology.

CCS is working with Labor Dr Wisplinghoff to create a European APAS® centre of excellence to test automation efficiency and clinical validation, in a similar way to the evaluation completed at St Vincent's Hospital, Melbourne in November 2017. This collaboration aims to extend the current menu of microbiology applications where APAS® can be applied and to investigate innovative ways to streamline workflows through the use of APAS® technology.

Expanding into Europe is an important milestone to broaden distribution reach of APAS® Independence. Over the coming months the Labor Dr Wisplinghoff facility will conduct evaluation and validation procedures using APAS® Independence.

Brent Barnes, CEO and MD, LBT Innovations said:

"The placement of the instrument in Labor Dr Wisplinghoff, a globally recognised centre of excellence, gives the APAS® Independence a huge boost in credibility in Europe and progresses our commercialisation strategy. Our JV company CCS is focused on ensuring a successful evaluation to leverage this experience into other laboratories in Germany and select EU markets. It will also help us to roll out sales of our APAS® Independence instruments in the near future."

Dr Hilmar Wisplinghoff expanded on the collaboration, stating:

"This collaboration is another example of Labor Dr Wisplinghoff employing the latest technology to deliver quality and timely results to our clients. We hope that this collaboration will further benefit our clients and their patients by bringing together our clinical expertise and the artificial intelligence of the APAS® Independence instrument."

About the APAS® Independence instrument

APAS® is a breakthrough artificial intelligence technology for the automated imaging, image analysis, interpretation and reporting of growth on microbiology culture plates after incubation. The APAS® Independence improves the clinical efficiency of microbiology labs and enables faster diagnosis and reporting of infectious diseases. The US FDA-cleared technology is based on LBT's Australian-developed intelligent imaging and machine learning software.

Microbiologists around the world currently manually review each agar plate, up to 90% of which are negative. APAS® Independence automatically reviews and sorts plates into neat stacks of negatives, positives and those to be reviewed. The APAS® Independence reads and interprets 200 plates per hour, at least three times faster than a manual read by microbiologists. It has demonstrated greater accuracy than microbiologists in independent clinical trials.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has two world class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and Automated Plate Assessment System (APAS®). Based on LBT's intelligent imaging and interpretative software, US FDA-cleared APAS® automates imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH to commercialise APAS® products. LBT's third product WoundVue® is in early development; this is a proposed automated solution to assist in the management of chronic wounds.

CONTACTS

LBT Innovations	Investor Enquiries	Media Relations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com	Sarah Kemter Monsoon Communications Tel: +61 3 9620 3333 E: sarahk@monsoon.com.au